Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

17.80 -0.24 (-1.33%)
Streaming Delayed Price Updated: 11:13 AM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial ↗
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial. 
Via Benzinga
News headline image
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Zai Lab Announces Participation in Investor Conferences in June 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire
News headline image
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio? ↗
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
News headline image
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Why ZAI LAB LTD-ADR (NASDAQ:ZLAB) could fit Mark Minervini’s high-growth criteria ↗
A fundamental and technical analysis of (NASDAQ:ZLAB): Why the high growth investor may take a look at ZAI LAB LTD-ADR (NASDAQ:ZLAB). 
Via Chartmill
News headline image
No Fear And No Panic After A 10% Correction = No Bottom ↗
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in March 2025
From Zai Lab Limited
Via Business Wire
News headline image
NovoCure Q4 EPS Misses, Revenue Matches ↗
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
News headline image
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.